

Active substances set

Search phrase: dasatinib

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Acute lymphoid leukemia

Dasatinib

Dasatinib is indicated for the treatment of adult patients with Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy. Dasatinib is indicated for the treatment of paediatric patients with newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.



**REIMBURSEMENT
WITH RESTRICTIONS**



ESMO